Time

PM

Date



Alzheimer Therapeutics Program (ATP) PATIENT CONSENT TO TREATMENT WITH A MONOCLONAL ANTIBODY FO	OR ALZHEIMER D	DISEASE	
I allow [Provider Name]and my o	care team in the ATP	to treat	
me with [drug name]			
I have been told the risks and benefits of this treatment. I also know that there are othe the risks and benefits of these other choices.	er choices to treat m	y condition. I	understand
I understand that all medical care involves some uncertainty. I understand there is no g medication.	uarantee that I will g	get the benefit	ts of this
My care team explained the risks below:			
 Reactions to the medication going in the vein, including fever, chills, b Areas of swelling and associated bleeding in the brain. In rare cases, thospitalization, or even cause death. 			
 The risk of swelling and bleeding are increased if I have a certain gene explained if my risks are higher. 	. My team has teste	d me for this g	gene and
I have been told how often I will be receiving treatments, the ways in which I will be care that would require me to seek urgent medical attention.	efully monitored, an	d the kinds of	symptoms
I understand that my care team may stop treatments if I experience serious side effects considered to have moderately severe, rather than mild disease.	or if I decline to the	point in which	n I would be
I have received teaching materials that help me understand the information explained t the treatment in more detail. I understand that the treatment may have unexpected sic			
I understand that other people may be in the room during my treatments. This includes ATP care team.	observers, nurses, o	or other meml	bers of the
I had a chance to ask questions about the risks, benefits, and side effects of the medical questions about the chances of achieving the goals of the treatment and other options. the treatment.			
			AM
Patient/Legal Surrogate Decision Maker Signature Printed Name	Date	Time	PM
I, the medical provider in the ATP, attest that I have discussed all the relevant as indications, risks, and benefits, as compared with alternative approaches, with t	•		-
			A N 4

Printed Name

Attending/Practitioner Signature